Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Goodwill & Intangibles (2016 - 2025)

Plus Therapeutics has reported Goodwill & Intangibles over the past 16 years, most recently at $705000.0 for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 16.17% to $705000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $705000.0 through Dec 2025, down 16.17% year-over-year, with the annual reading at $705000.0 for FY2025, 16.17% down from the prior year.
  • Goodwill & Intangibles was $705000.0 for Q4 2025 at Plus Therapeutics, down from $746000.0 in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $929000.0 in Q2 2024 and troughed at $405000.0 in Q1 2024.
  • The 5-year median for Goodwill & Intangibles is $475500.0 (2022), against an average of $576700.0.
  • Year-over-year, Goodwill & Intangibles skyrocketed 113.07% in 2024 and then fell 16.79% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $423000.0 in 2021, then increased by 10.17% to $466000.0 in 2022, then dropped by 11.16% to $414000.0 in 2023, then skyrocketed by 103.14% to $841000.0 in 2024, then fell by 16.17% to $705000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Goodwill & Intangibles are $705000.0 (Q4 2025), $746000.0 (Q3 2025), and $773000.0 (Q2 2025).